Amyloid oligomers: A joint experimental/computational perspective on Alzheimer's disease, Parkinson's disease, type II diabetes, and amyotrophic lateral sclerosis
Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the
Alzheimer disease (AD) process. Aβ accumulation begins 15–20 years before clinical …
Alzheimer disease (AD) process. Aβ accumulation begins 15–20 years before clinical …
Challenges and hopes for Alzheimer's disease
SA Tatulian - Drug discovery today, 2022 - Elsevier
Recent drug development efforts targeting Alzheimer's disease (AD) have failed to produce
effective disease-modifying agents for many reasons, including the substantial …
effective disease-modifying agents for many reasons, including the substantial …
The amyloid-β oligomer hypothesis: beginning of the third decade
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …
Practical considerations for choosing a mouse model of Alzheimer's disease
JL Jankowsky, H Zheng - Molecular neurodegeneration, 2017 - Springer
Alzheimer's disease (AD) is behaviorally identified by progressive memory impairment and
pathologically characterized by the triad of β-amyloid plaques, neurofibrillary tangles, and …
pathologically characterized by the triad of β-amyloid plaques, neurofibrillary tangles, and …
Amyloid-β and tau complexity—towards improved biomarkers and targeted therapies
Most neurodegenerative diseases are proteinopathies, which are characterized by the
aggregation of misfolded proteins. Although many proteins have an intrinsic propensity to …
aggregation of misfolded proteins. Although many proteins have an intrinsic propensity to …
Relationship between amyloid-β deposition and blood–brain barrier dysfunction in Alzheimer's disease
D Wang, F Chen, Z Han, Z Yin, X Ge… - Frontiers in Cellular …, 2021 - frontiersin.org
Amyloid-β (Aβ) is the predominant pathologic protein in Alzheimer's disease (AD). The
production and deposition of Aβ are important factors affecting AD progression and …
production and deposition of Aβ are important factors affecting AD progression and …
[HTML][HTML] Melatonin regulates Aβ production/clearance balance and Aβ neurotoxicity: A potential therapeutic molecule for Alzheimer's disease
Y Li, J Zhang, J Wan, A Liu, J Sun - Biomedicine & Pharmacotherapy, 2020 - Elsevier
Alzheimer's disease (AD) is an age-related neurodegenerative disease with multiple
predisposing factors and complicated pathogenesis. Aβ peptide is one of the most important …
predisposing factors and complicated pathogenesis. Aβ peptide is one of the most important …
SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers
D Shea, E Colasurdo, A Smith… - Proceedings of the …, 2022 - National Acad Sciences
The formation of toxic Amyloid β-peptide (Aβ) oligomers is one of the earliest events in the
molecular pathology of Alzheimer's Disease (AD). These oligomers lead to a variety of …
molecular pathology of Alzheimer's Disease (AD). These oligomers lead to a variety of …
Aβ-oligomers: A potential therapeutic target for Alzheimer's disease
The cascade of amyloid formation relates to multiple complex events at the molecular level.
Previous research has established amyloid plaque deposition as the leading cause of …
Previous research has established amyloid plaque deposition as the leading cause of …